Glaukos Corporation

Equities

GKOS

US3773221029

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:02 2024-03-28 pm EDT 5-day change 1st Jan Change
94.29 USD +1.73% Intraday chart for Glaukos Corporation +7.74% +18.62%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Glaukos Insider Sold Shares Worth $1,153,557, According to a Recent SEC Filing MT
Glaukos Insider Sold Shares Worth $736,000, According to a Recent SEC Filing MT
Glaukos Insider Sold Shares Worth $423,487, According to a Recent SEC Filing MT
Wells Fargo Hikes Price Target on Glaukos to $103 From $83, Maintains Overweight Rating MT
Needham Raises Price Target on Glaukos to $108 From $105, Maintains Buy Rating MT
Glaukos Q4 Non-GAAP Loss Widens, Sales Increase MT
Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q4 Revenue $82.4M, vs. Street Est of $78.5M MT
Transcript : Glaukos Corporation, Q4 2023 Earnings Call, Feb 21, 2024
Glaukos Corporation Reaffirms Financial Guidance for 2024 CI
Glaukos Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Glaukos Insider Sold Shares Worth $436,041, According to a Recent SEC Filing MT
Transcript : Glaukos Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 05:15 PM
Glaukos Preliminary Q4 Net Sales Top Estimates; 2024 Revenue Outlook Reaffirmed; Shares Rise MT
Glaukos Corporation Announces Preliminary and Unaudited Net Sales for the Fourth Quarter and Full Year of 2023; Reaffirms Net Sales Guidance for the Year 2024 CI
Glaukos Insider Sold Shares Worth $7,334,253, According to a Recent SEC Filing MT
North American Morning Briefing : Dow Futures Fall -2- DJ
Piper Sandler Raises Price Target on Glaukos to $105 From $90, Maintains Overweight Rating MT
JPMorgan Upgrades Glaukos to Overweight From Neutral, Raises Price Target to $91 From $66 MT
Sector Update: Health Care Stocks Slipping Late Afternoon MT
Sector Update: Health Care MT
Glaukos Shares Jump After US FDA Approves New Drug Application for iDose TR MT
Sector Update: Health Care Stocks Rise Pre-Bell Thursday MT
Glaukos Says FDA Approves New Drug Application for iDose TR MT
Transcript : Glaukos Corporation - Special Call
FDA Approves Glaukos' New Drug Application for iDose TR DJ
Chart Glaukos Corporation
More charts
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
92.69 USD
Average target price
104.2 USD
Spread / Average Target
+12.38%
Consensus
  1. Stock
  2. Equities
  3. Stock Glaukos Corporation - Nyse
  4. News Glaukos Corporation
  5. Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q2 Loss $-1.21